Google
BCLI — BRAINSTORM CELL THERAPEUTICS INC (Healthcare >> Biotechnology)
BCLI FAQ
What is BCLI's ROE?
BRAINSTORM CELL THERAPEUTICS INC reports a Return on Equity (ROE) of 86.93%.
What is BCLI's dividend yield?
BRAINSTORM CELL THERAPEUTICS INC offers a dividend yield of 0.00%.
What is BCLI's Deepscope Quality Score?
Deepscope rates BCLI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BCLI?
Deepscope's AI Timing Score for BCLI is 5 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BCLI belong to?
BRAINSTORM CELL THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 0.80
Price
-0.05
(-5.54%)
Day Change
|
|
|---|
BCLI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 54 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.80 |
| PBV / Sector |
-0.74 / 4.75
|
| Earning Per Share | -0.93 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
2885.827095000000
|
| Average 1W Daily Value |
2964.725580000000
|
| Timing Factors |
|
85% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
45% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-09 09:40:03 |
| Symbol | BCLI |
| Name | BRAINSTORM CELL THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 11.03 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.28 / 9,000.42 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1325 Avenue of Americas, New York, NY, United States, 10019
Phone: 201 488 0460
Website: https://www.brainstorm-cell.com
Sector: Healthcare >> Biotechnology
Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of Alzheimer's disease, as well as for treatment of other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
